AbCellera Biologics (ABCL) Enterprise Value (2020 - 2026)

AbCellera Biologics has reported Enterprise Value for 7 years, with the latest figure at -$102.1 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 83.81% year-over-year to -$102.1 million; the trailing twelve-month figure through Mar 2026 stood at -$102.1 million (up 83.81% YoY), and the FY2025 full-year result was -$558.8 million, up 14.11% from the prior year.
• Enterprise Value for Q1 2026 stood at -$102.1 million, up from -$558.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$102.1 million in Q1 2026, with the low at -$911.5 million in Q4 2022.
• Historically, Enterprise Value has averaged -$506.1 million across 5 years, with a median of -$558.8 million in 2025.
• Annual changes were most pronounced in 2024 — Enterprise Value slumped 310.95% — and 2026, when it jumped 83.81%.
• AbCellera Biologics' Enterprise Value stood at -$911.5 million in 2022, then soared by 82.63% to -$158.3 million in 2023, then tumbled by 310.95% to -$650.6 million in 2024, then rose by 14.11% to -$558.8 million in 2025, then surged by 81.74% to -$102.1 million in 2026.
• The last three Enterprise Value figures came in at -$102.1 million (Q1 2026), -$558.8 million (Q4 2025), and -$520.7 million (Q3 2025), per Business Quant data.